Published in Am J Pathol on October 15, 2010
AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One (2011) 0.86
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn (2015) 0.77
Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. Br J Dermatol (2012) 0.75
Case-control study of candidate gene methylation and adenomatous polyp formation. Int J Colorectal Dis (2016) 0.75
Epigenetics in cancer. N Engl J Med (2008) 17.36
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A (1999) 13.02
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A (1998) 3.90
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology (2002) 3.70
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A (2000) 3.65
Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res (1999) 3.48
Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res (1997) 3.09
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res (2008) 2.83
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology (2008) 2.64
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
Serrated adenoma of the colorectum and the DNA-methylator phenotype. Nat Clin Pract Oncol (2005) 2.08
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res (2009) 2.03
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res (2009) 2.02
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol (2002) 1.83
Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol (2003) 1.82
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 1.68
High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res (2003) 1.68
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol (2003) 1.67
Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res (2002) 1.67
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer. Gut (2004) 1.53
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res (2005) 1.38
Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res (2007) 1.33
Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn (2006) 1.30
Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer (2004) 1.28
Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer (2008) 1.27
Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer (2005) 1.26
Synthesis of universal unmethylated control DNA by nested whole genome amplification with phi29 DNA polymerase. Biochem Biophys Res Commun (2005) 1.26
Emerging pathways in colorectal-cancer development. Lancet Oncol (2002) 1.20
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res (2005) 1.15
Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins. Gut (2006) 1.11
Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation. Clin Cancer Res (2005) 1.07
Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles. Mol Cancer Res (2007) 1.05
Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res (2004) 1.00
Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol (2001) 0.98
Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J Clin Oncol (2008) 0.97
Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. J Mol Diagn (2009) 0.96
Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. Clin Cancer Res (2007) 0.95
DNA methylation patterns in adenomas from FAP, multiple adenoma and sporadic colorectal carcinoma patients. Int J Cancer (2006) 0.92
Epigenetic changes in cancer and preneoplasia. Cold Spring Harb Symp Quant Biol (2005) 0.91
CpG island methylation in aberrant crypt foci and cancers from the same patients. Int J Cancer (2005) 0.84
Methylation of p16 and Ras association domain family protein 1a during colorectal malignant transformation. Mol Cancer Res (2006) 0.84
When does MMR loss occur during HNPCC progression? Cancer Biomark (2006) 0.80
Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps. Am J Clin Pathol (2004) 0.78
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med (2004) 8.91
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Gastric cancer. Lancet (2009) 7.27
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol (2010) 6.60
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 5.75
Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat Genet (2011) 5.70
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 4.61
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg (2007) 4.22
Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol (2002) 4.02
Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J Surg Oncol (2011) 3.24
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol (2002) 3.09
Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol (2013) 3.01
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology (2004) 2.90
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 2.72
Toward optimization of imaging system and lymphatic tracer for near-infrared fluorescent sentinel lymph node mapping in breast cancer. Ann Surg Oncol (2011) 2.67
Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol (2011) 2.58
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol (2014) 2.39
Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol (2005) 2.33
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. J Clin Oncol (2010) 2.29
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol (2006) 2.28
External validity of a trial comprised of elderly patients with hormone receptor-positive breast cancer. J Natl Cancer Inst (2014) 2.26
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol (2012) 2.20
Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol (2013) 2.17
Optical image-guided surgery--where do we stand? Mol Imaging Biol (2011) 2.15
Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J Surg Oncol (2013) 2.12
A multivariate analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total mesorectal excision (TME) trial: a retrospective study. Lancet Oncol (2007) 2.12
Short-term preoperative radiotherapy interferes with the determination of pathological parameters in rectal cancer. J Pathol (2002) 2.11
Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis. Eur J Cancer (2012) 2.07
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest (2004) 2.05
EMT is the dominant program in human colon cancer. BMC Med Genomics (2011) 2.05
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol (2010) 2.04
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem (2010) 2.03
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med (2015) 2.01
Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. JAMA (2012) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: a first in human experience. J Urol (2013) 1.97
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients. Breast Cancer Res Treat (2011) 1.89
Causes of fecal and urinary incontinence after total mesorectal excision for rectal cancer based on cadaveric surgery: a study from the Cooperative Clinical Investigators of the Dutch total mesorectal excision trial. J Clin Oncol (2008) 1.87
The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol (2012) 1.87
Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat (2010) 1.83
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet (2003) 1.80
Chromosome 8q23.3 and 11q23.1 variants modify colorectal cancer risk in Lynch syndrome. Gastroenterology (2008) 1.79
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol (2009) 1.78
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer (2011) 1.76
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer. J Clin Oncol (2009) 1.74
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res (2003) 1.73
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol (2006) 1.72
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist (2010) 1.72
Near-infrared fluorescence-guided resection of colorectal liver metastases. Cancer (2013) 1.71
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res (2005) 1.70
Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 1.68
EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol (2004) 1.68
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol (2003) 1.67
Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer (2007) 1.67
LINE-1 hypomethylation during primary colon cancer progression. PLoS One (2011) 1.66
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology (2008) 1.61
The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol (2007) 1.61